STOCK TITAN

Caribou Biosciences (CRBU) Stock News

CRBU NASDAQ

Caribou Biosciences develops CRISPR genome-edited, allogeneic CAR-T cell therapies for hematologic malignancies. Company updates center on vispacabtagene regedleucel, or vispa-cel, an anti-CD19 CAR-T therapy being evaluated in B cell non-Hodgkin lymphoma and large B cell lymphoma, and CB-011, an anti-BCMA CAR-T therapy for relapsed or refractory multiple myeloma.

Recurring announcements include clinical and translational data from the ANTLER and CaMMouflage trials, FDA designations and trial-design interactions, financial results, research and development spending, cash resources, pipeline prioritization, and medical or investor conference participation.

Rhea-AI Summary

Caribou Biosciences (Nasdaq: CRBU) reported a narrower third-quarter 2026 net loss while preparing to discontinue development of both clinical programs. GAAP net loss was $26.612 million, or $0.25 per share, versus $27.548 million, or $0.30 per share, a year earlier. Licensing and other third-party revenue fell to $1.607 million from $2.198 million. Research and administrative expenses both declined.

Cash, cash equivalents and marketable securities totaled $94.800 million at September 30, versus $142.845 million at December 31, 2025. The restructuring announced October 6 includes planned discontinuation of vispa-cel and CB-011 trials and development, a substantial workforce reduction and other cost cuts. Caribou cited financing challenges. Its strategic review may include a merger, acquisition, other transactions, or dissolution and liquidation; no completion timeline has been set.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.83%
Tags
-
Rhea-AI Summary

Caribou Biosciences (Nasdaq: CRBU) announced acceptance of clinical abstracts for three presentations at the December 12–15, 2026 ASH Annual Meeting.

Two oral presentations and one poster in New Orleans will cover vispa-cel findings from the ANTLER lymphoma trial and CB-011 findings from the CaMMouflage multiple myeloma trial. The abstracts were submitted before Caribou announced plans to explore strategic alternatives and discontinue further development of both programs. Caribou cited the current financing environment for allogeneic CAR-T cell therapies as the reason. Investigators will present findings despite those plans.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.27%
Tags
none
-
Rhea-AI Summary

Caribou Biosciences (Nasdaq: CRBU) is exploring strategic alternatives and plans to discontinue development of its two donor-derived CAR-T cell therapy programs.

The board-approved review includes a potential merger, acquisition, business combination or transactions involving Caribou or its assets. Wedbush Securities is the exclusive financial advisor; no completion timeline has been set. Development would stop for vispa-cel in relapsed or refractory B cell non-Hodgkin lymphoma and CB-011 in relapsed or refractory multiple myeloma. Caribou cited difficulty securing capital in the current financing environment, despite FDA alignment on vispa-cel's phase 3 trial design.

Caribou plans cost reductions and a workforce reduction expected to be mostly complete in Q4 2026. Cash, cash equivalents and marketable securities totaled $113.8 million as of June 30, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-45.60%
Tags
none
Rhea-AI Summary

Caribou Biosciences (Nasdaq: CRBU) reported second quarter 2026 results and key updates on its allogeneic CAR-T pipeline. In the ANTLER phase 1 trial, vispacabtagene regedleucel (vispa-cel) in second-line large B cell lymphoma showed an 82% overall response rate, 67% complete response rate, 17.1-month median progression-free survival, and a generally well-tolerated safety profile in 27 optimized patients treated with a single 80 million cell dose.

In the CaMMouflage phase 1 trial, CB-011 in 12 BCMA-naïve relapsed/refractory multiple myeloma patients at the 450 million cell dose achieved a 92% overall response rate, 83% ≥CR rate, and 91% MRD negativity in evaluable patients. Q2 2026 licensing and other revenue was $1.5 million, R&D expenses $18.9 million, G&A expenses $7.9 million, and GAAP net loss $24.3 million ($0.24 per share). Caribou ended June 30, 2026 with $113.8 million in cash, cash equivalents, and marketable securities and expects this to fund operations into the end of 2027, including CB-011 dose expansion and ANTLER-3 start-up activities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.86%
Tags
-
Rhea-AI Summary

Caribou Biosciences (Nasdaq: CRBU) announced that president and CEO Rachel Haurwitz, PhD, will participate in a fireside chat at the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on June 30, 2026, at 10:00 am ET.

Investors can access a webcast via the Events page on Caribou’s website, where replays will remain available for at least 30 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.36%
Tags
none
-
Rhea-AI Summary

Caribou Biosciences (Nasdaq: CRBU) reported long-term ANTLER phase 1 data for vispa-cel, an allogeneic CD19 CAR-T, in second-line large B cell lymphoma (2L LBCL). In 27 optimized-dose patients, a single 80-million-cell infusion achieved 82% ORR, 67% CR, and 17.1-month median PFS.

The safety profile showed no graft-versus-host disease, no ≥grade 3 ICANS, one (4%) ≥grade 3 CRS, and serious infections and cytopenias in some patients. Caribou outlined the ANTLER-3 pivotal phase 3 trial, enrolling ~250 CD19-naïve 2L LBCL patients versus standard regimens, with PFS as the primary endpoint.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.26%
Tags
none
Rhea-AI Summary

Caribou Biosciences (Nasdaq: CRBU) reported longer follow up data from the phase 1 CaMMouflage trial of CB-011, an off-the-shelf BCMA-targeted CAR-T for relapsed/refractory multiple myeloma.

At the recommended dose, a single infusion showed high response rates, deep MRD-negative remissions, and a manageable safety profile, plus a detailed case after prior BCMA CAR-T.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.26%
Tags
none
-
Rhea-AI Summary

Caribou Biosciences (Nasdaq: CRBU) announced that president and CEO Rachel Haurwitz, PhD, will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 4, 2026, at 2:35 p.m. ET in New York.

The live and archived webcasts will be accessible via the Events page on Caribou’s website for at least 30 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
none
-
Rhea-AI Summary

Caribou Biosciences (Nasdaq: CRBU) announced that its management team will participate in a fireside chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026 at 12:30 p.m. ET in New York.

A live webcast and replay will be available for at least 30 days on the Events page of Caribou’s website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.94%
Tags
none
Rhea-AI Summary

Caribou Biosciences (Nasdaq: CRBU) will feature its allogeneic CAR-T programs vispa-cel and CB-011 in oral presentations at the 2026 European Hematology Association Annual Meeting in Stockholm, June 11-14, 2026.

Presentations cover ANTLER and CaMMouflage phase 1 trials in lymphoma and multiple myeloma.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
none

FAQ

What is the current stock price of Caribou Biosciences (CRBU)?

Caribou Biosciences (CRBU) last closed at $0.2843.

What is the market cap of Caribou Biosciences (CRBU)?

The market cap of Caribou Biosciences (CRBU) is approximately $30.7M.